Novoheart Holdings Inc. Reports Earnings Results for the Full Year Ended June 30, 2019

Novoheart Holdings Inc is a Canada-based holding company. The Company, through its subsidiary, provides, discovers and develops heart therapeutics. Novoheart's scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including first human mini-heart “novoHeart” that is capable of fully capable of pumping and ejecting fluid. It is currently partnering with a pharmaceutical company to develop human heart tissues and chambers that carry a hereditary neurodegenerative disease. It is anticipated that the pharmaceutical company will be able to use the developed pathological tissues as a unique drug discovery and drug screening platform for effective therapies targeting the heart-associated issues of this specific disease. Novoheart is currently completing the build out a large commercial laboratory in Asia to enable it to service additional potential commercial partnerships, which are under discussion.